Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

In the same year, it also created the Novartis Institutes for BioMedical Research (NIBR), which headquarters in the US. In 2003, Novartis acquired the worldwide adult medical nutrition business of ...

How would you summarize your study for a lay audience?Heart failure remains a substantial burden for patients due to its high ...

New licensing Guidelines issued by the National Institutes of Health at the end of the Biden Administration could harm ...

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

At NYU Grossman School of Medicine, our Vilcek Institute of Graduate Biomedical Sciences offers qualified college students who have completed their sophomore or junior year the opportunity to ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Deutsche Bank upgraded Novartis (NVS) to Buy from Hold with a price target of CHF 110, up from CHF 100. The firm says the company’s ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...